Results from a clinical trial targeting T1D (NCT01210664) showed that 14 adult patients with T1D received ex vivo–expanded autologous CD4+CD127lo/−CD25+ polyclonal Tregs, with a subset of reinfused Tregs exhibiting long-lasting survival (53). This evidence concerns the gene CD4 and type 1 diabetes mellitus.